JP2020501517A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020501517A5 JP2020501517A5 JP2019522657A JP2019522657A JP2020501517A5 JP 2020501517 A5 JP2020501517 A5 JP 2020501517A5 JP 2019522657 A JP2019522657 A JP 2019522657A JP 2019522657 A JP2019522657 A JP 2019522657A JP 2020501517 A5 JP2020501517 A5 JP 2020501517A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cdna
- subject
- drug
- droplets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022142901A JP7441907B2 (ja) | 2016-10-27 | 2022-09-08 | 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662413952P | 2016-10-27 | 2016-10-27 | |
| US62/413,952 | 2016-10-27 | ||
| PCT/US2017/058855 WO2018081625A2 (en) | 2016-10-27 | 2017-10-27 | Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022142901A Division JP7441907B2 (ja) | 2016-10-27 | 2022-09-08 | 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020501517A JP2020501517A (ja) | 2020-01-23 |
| JP2020501517A5 true JP2020501517A5 (enExample) | 2020-12-03 |
| JP7195252B2 JP7195252B2 (ja) | 2022-12-23 |
Family
ID=62025512
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522657A Active JP7195252B2 (ja) | 2016-10-27 | 2017-10-27 | 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析 |
| JP2022142901A Active JP7441907B2 (ja) | 2016-10-27 | 2022-09-08 | 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022142901A Active JP7441907B2 (ja) | 2016-10-27 | 2022-09-08 | 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11371101B2 (enExample) |
| EP (2) | EP3532642B1 (enExample) |
| JP (2) | JP7195252B2 (enExample) |
| CN (1) | CN110050075B (enExample) |
| WO (1) | WO2018081625A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3274476B1 (en) | 2015-03-25 | 2023-06-07 | The General Hospital Corporation | Digital analysis of circulating tumor cells in blood samples |
| CN110050075B (zh) * | 2016-10-27 | 2024-04-02 | 通用医疗公司 | 用于确定特定癌症的癌症疗法的功效的血液样品的数字分析 |
| WO2020006098A2 (en) * | 2018-06-26 | 2020-01-02 | Children's National Medical Center | Tumor-associated markers for detection of minimal residual disease using digital droplet pcr |
| MX2021005662A (es) * | 2018-11-14 | 2021-10-13 | Broad Inst Inc | Compuestos activadores del receptor de aril hidrocarburo (ahr) como agentes terapéuticos para el cáncer. |
| TWI790399B (zh) * | 2019-08-30 | 2023-01-21 | 長庚大學 | 循環腫瘤細胞資訊評估方法及其分析方法 |
| WO2021055517A1 (en) * | 2019-09-16 | 2021-03-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treatments based upon molecular characterization of breast cancer |
| CN116034273A (zh) * | 2020-09-09 | 2023-04-28 | 株式会社日立高新技术 | 利用代谢物面板的癌症检查法 |
| CN112698033A (zh) * | 2020-12-09 | 2021-04-23 | 复旦大学附属中山医院 | 一种血源性外泌体her2的检测方法及其应用 |
| WO2022196186A1 (ja) * | 2021-03-16 | 2022-09-22 | ソニーグループ株式会社 | 閉鎖系の自動試料分取システム |
| CN113292643A (zh) * | 2021-05-31 | 2021-08-24 | 南京市第二医院 | 一种肝癌肿瘤标志物及其应用 |
| CN117940214A (zh) * | 2021-07-08 | 2024-04-26 | 欧罗科技公司 | 治疗功效预测系统和方法 |
| CN114395622A (zh) * | 2021-12-13 | 2022-04-26 | 深圳先进技术研究院 | 一种利用数字pcr检测循环肿瘤细胞egfr基因突变的方法及其应用 |
| WO2025259592A1 (en) * | 2024-06-10 | 2025-12-18 | Genecentric Therapeutics, Inc. | Therapeutic predictive response signatures and uses thereof in cancer patients |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US889A (en) | 1838-08-20 | Mode of constructing metal bench-vises | ||
| US8535A (en) | 1851-11-18 | Stove-geate | ||
| DE29623597U1 (de) | 1996-11-08 | 1999-01-07 | Eppendorf - Netheler - Hinz Gmbh, 22339 Hamburg | Temperierblock mit Temperiereinrichtungen |
| US20080050393A1 (en) | 1998-12-03 | 2008-02-28 | Tang Y Tom | Novel nucleic acids and polypeptides |
| CA2311201A1 (en) | 1999-08-05 | 2001-02-05 | Genset S.A. | Ests and encoded human proteins |
| AU2002234799A1 (en) | 2000-12-08 | 2002-06-18 | Ipsogen | Gene expression profiling of primary breast carcinomas using arrays of candidate genes |
| CN1526025A (zh) | 2001-05-16 | 2004-09-01 | ��˹��ŵ�� | 作为预后和治疗靶标的乳腺癌中表达的基因 |
| US20030073623A1 (en) | 2001-07-30 | 2003-04-17 | Drmanac Radoje T. | Novel nucleic acid sequences obtained from various cDNA libraries |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20060275794A1 (en) | 2005-03-07 | 2006-12-07 | Invitrogen Corporation | Collections of matched biological reagents and methods for identifying matched reagents |
| US20070026417A1 (en) | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| US20090118175A1 (en) * | 2005-05-06 | 2009-05-07 | Macina Roberto A | Compositions and Methods for Detection, Prognosis and Treatment of Breast Cancer |
| US20090275486A1 (en) | 2006-05-16 | 2009-11-05 | Nurith Kurn | Nucleic acid separation and purification method based on reversible charge interactions |
| US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
| WO2009051734A1 (en) | 2007-10-17 | 2009-04-23 | The General Hospital Corporation | Microchip-based devices for capturing circulating tumor cells and methods of their use |
| US9068181B2 (en) | 2008-05-23 | 2015-06-30 | The General Hospital Corporation | Microfluidic droplet encapsulation |
| US20120252015A1 (en) | 2011-02-18 | 2012-10-04 | Bio-Rad Laboratories | Methods and compositions for detecting genetic material |
| WO2010037134A2 (en) | 2008-09-29 | 2010-04-01 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
| US9625454B2 (en) | 2009-09-04 | 2017-04-18 | The Research Foundation For The State University Of New York | Rapid and continuous analyte processing in droplet microfluidic devices |
| US20110166030A1 (en) | 2009-09-30 | 2011-07-07 | Yixin Wang | Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells |
| EP4435111A1 (en) | 2010-02-12 | 2024-09-25 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| US20120329061A1 (en) | 2010-03-11 | 2012-12-27 | Board Of Regents, The University Of Texas System | Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of cancer patients |
| PL2553118T3 (pl) * | 2010-03-31 | 2015-03-31 | Sividon Diagnostics Gmbh | Sposób przewidywania nawrotu raka sutka podczas leczenia endokrynologicznego |
| AU2015268617A1 (en) * | 2010-03-31 | 2016-01-07 | Sividon Diagnostics Gmbh | Method for breast cancer recurrence prediction under endocrine treatment |
| US9650629B2 (en) | 2010-07-07 | 2017-05-16 | Roche Molecular Systems, Inc. | Clonal pre-amplification in emulsion |
| US20140148350A1 (en) * | 2010-08-18 | 2014-05-29 | David Spetzler | Circulating biomarkers for disease |
| JP2014507160A (ja) | 2011-02-22 | 2014-03-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． | 循環バイオマーカー |
| WO2012135397A2 (en) * | 2011-03-29 | 2012-10-04 | Lisanti Michael P | Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome |
| US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
| WO2013063035A1 (en) | 2011-10-24 | 2013-05-02 | The General Hospital Corporation | Biomarkers of cancer |
| US9766244B2 (en) | 2012-07-02 | 2017-09-19 | The General Hospital Corporation | Diagnosis and monitoring treatment of prostate cancer |
| WO2014028378A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Methods and systems for detecting biological components |
| CA2884820A1 (en) | 2012-09-14 | 2014-03-20 | Memorial Sloan-Kettering Cancer Center | Genes associated with dasatinib sensitivity |
| WO2014047285A1 (en) | 2012-09-19 | 2014-03-27 | Paraskevi Giannakakou | Identifying taxane sensitivity in prostate cancer patients |
| US20140154681A1 (en) * | 2012-11-12 | 2014-06-05 | Nanostring Technologies, Inc. | Methods to Predict Breast Cancer Outcome |
| US20140303005A1 (en) | 2013-04-05 | 2014-10-09 | Raindance Technologies, Inc. | Rare cell analysis after negative selection |
| WO2015023710A1 (en) * | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| US10202577B2 (en) | 2013-10-18 | 2019-02-12 | The General Hospital Corporation | Microfluidic sorting using high gradient magnetic fields |
| AU2015228860A1 (en) * | 2014-03-13 | 2016-09-08 | F. Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
| CN106456776A (zh) * | 2014-05-21 | 2017-02-22 | 豪夫迈·罗氏有限公司 | 用PI3K抑制剂Pictilisib治疗PR阳性腔性A乳腺癌的方法 |
| US20170343554A1 (en) * | 2014-12-12 | 2017-11-30 | Celcuity Llc | Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients |
| CN107250385B (zh) | 2015-02-20 | 2021-03-09 | 考麦兹股份公司 | 用于切割天然皮革及类似物的方法 |
| CA2979226A1 (en) | 2015-03-12 | 2016-09-15 | Janssen Pharmaceutica Nv | Whole blood based mrna markers for predicting prostate cancer and methods of detecting the same |
| EP3274476B1 (en) | 2015-03-25 | 2023-06-07 | The General Hospital Corporation | Digital analysis of circulating tumor cells in blood samples |
| CN110050075B (zh) * | 2016-10-27 | 2024-04-02 | 通用医疗公司 | 用于确定特定癌症的癌症疗法的功效的血液样品的数字分析 |
-
2017
- 2017-10-27 CN CN201780075515.XA patent/CN110050075B/zh active Active
- 2017-10-27 JP JP2019522657A patent/JP7195252B2/ja active Active
- 2017-10-27 EP EP17865612.0A patent/EP3532642B1/en active Active
- 2017-10-27 US US16/344,557 patent/US11371101B2/en active Active
- 2017-10-27 EP EP21212237.8A patent/EP3985127A1/en active Pending
- 2017-10-27 WO PCT/US2017/058855 patent/WO2018081625A2/en not_active Ceased
-
2022
- 2022-05-27 US US17/826,834 patent/US12331363B2/en active Active
- 2022-09-08 JP JP2022142901A patent/JP7441907B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020501517A5 (enExample) | ||
| Sato et al. | DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells | |
| Wang et al. | Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor | |
| Mego et al. | Expression of epithelial–mesenchymal transition‐inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy | |
| Blassl et al. | Gene expression profiling of single circulating tumor cells in ovarian cancer–Establishment of a multi-marker gene panel | |
| Vriens et al. | MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer | |
| Singh et al. | Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells | |
| Redis et al. | CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations | |
| Zhang et al. | Up-regulation of LncRNA SNHG20 predicts poor prognosis in hepatocellular carcinoma | |
| Song et al. | Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients | |
| Markou et al. | Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up | |
| MacConaill et al. | Prospective enterprise-level molecular genotyping of a cohort of cancer patients | |
| Chan et al. | SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients | |
| Takeshita et al. | Prognostic role of PIK 3 CA mutations of cell‐free DNA in early‐stage triple negative breast cancer | |
| Lieb et al. | Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients | |
| US20170107577A1 (en) | Determining Cancer Aggressiveness, Prognosis and Responsiveness to Treatment | |
| Kulda et al. | Prognostic significance of TMPRSS2-ERG fusion gene in prostate cancer | |
| Chang et al. | Review of microRNA in osteosarcoma and chondrosarcoma | |
| Peng et al. | Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma | |
| Chimonidou et al. | Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer | |
| Liu et al. | Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer | |
| Schubert et al. | Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development? | |
| Marino et al. | Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression | |
| Kowalczyk et al. | SATB1 is down-regulated in clear cell renal cell carcinoma and correlates with miR-21-5p overexpression and poor prognosis | |
| Suer et al. | MicroRNAs as prognostic markers in prostate cancer |